Jade Biosciences/$JBIO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Jade Biosciences
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
- Ticker
- $JBIO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 55
- Headquarters
- Waltham, United States
- Website
- jadebiosciences.com
Jade Biosciences Metrics
BasicAdvanced
$897M
-
-$2.34
-
-
Price and volume
Market cap
$897M
52-week high
$28.00
52-week low
$8.36
Average daily volume
901K
Financial strength
Current ratio
14.927
Quick ratio
14.609
Long term debt to equity
0.001
Total debt to equity
0.003
Interest coverage (TTM)
-45.76%
Profitability
EBITDA (TTM)
-164.702
Effective tax rate (TTM)
-0.06%
Management effectiveness
Valuation
Price to book
2.04
Price to tangible book (TTM)
2.04
Price to free cash flow (TTM)
-6.06
Free cash flow yield (TTM)
-16.50%
Free cash flow per share (TTM)
-2.327
Growth
What the Analysts think about Jade Biosciences
Analyst ratings (Buy, Hold, Sell) for Jade Biosciences stock.
Analyst projections of the future price of Jade Biosciences stock.
Bulls say / Bears say
JADE101 produced an encouraging Phase 1 biomarker signal: one 700 mg dose reduced IgA by about 70%, with reductions supporting possible 12-week maintenance dosing, and the treatment was well tolerated. That could offer both biological activity and less frequent injections if confirmed in patients. (Jade Biosciences)
Jade has begun its Phase 2 JADE101 trial and plans to start a registrational Phase 3 study in the first half of 2027, subject to FDA feedback. Moving towards a pivotal study before the Phase 2 interim readout could shorten the development timeline if regulators agree. (Jade Biosciences)
The company reported $461.2 million in cash, cash equivalents and investments at the end of June 2026, which it expects to fund operations into the fourth quarter of 2028. This gives Jade room to advance several programmes through near-term clinical milestones without an immediate financing need, based on its current plans. (Jade Biosciences)
The headline JADE101 results came from healthy volunteers and measured IgA levels, not kidney outcomes in people with IgA nephropathy. Its clinical benefit therefore remains unproven until patient-trial data arrive, with interim Phase 2 results expected in 2027. (Jade Biosciences)
JADE101 is entering a crowded IgA nephropathy market where rival treatments are already approved or advancing, including another APRIL-targeting drug. A potentially longer dosing interval may not be enough to win meaningful share against established competitors. (Investing.com)
Jade used $67.7 million in operating cash in the first half of 2026 and remains dependent on external funding while it develops its candidates. Its June $172.5 million share offering funded operations but also illustrates the dilution risk if costs rise or development takes longer than planned. (SEC, Jade Biosciences)
Data summarised monthly by Lightyear AI. Last updated on 16 Oct 2026.
Jade Biosciences Financial Performance
Revenues and expenses
Jade Biosciences Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Jade Biosciences
Fund name | Fund size | $JBIO weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.01% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.00% |
SPDR MSCI All Country World IM€SPYI | $7.7B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.